<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061603</url>
  </required_header>
  <id_info>
    <org_study_id>CS-200</org_study_id>
    <nct_id>NCT04061603</nct_id>
  </id_info>
  <brief_title>iCLAS™ for Persistent Atrial Fibrillation</brief_title>
  <official_title>iCLAS™ for Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adagio Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adagio Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study to evaluate the safety and efficacy of the Adagio AF Cryoablation System
      (iCLAS™) in the ablation treatment of symptomatic, persistent atrial fibrillation (PsAF).
      Data will be used to support a pre-market application (PMA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A staged pre-market, single-arm, clinical study designed to collect acute and long-term
      safety and efficacy data for the Adagio AF Cryoablation System (iCLAS™). Patient population
      will consist of symptomatic, persistent AF subjects completing a de novo ablation procedure.
      Enrollment will be 200 subjects at up to 20 global investigational sites. Subjects will
      receive an ablation with the ultra-low cryoablation device. Follow-up will include assessment
      at one, three, six, and twelve months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">December 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 9, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Symptomatic persistent atrial fibrillation that failed at least one class I or Class III AAD with no prior history of ablation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of the proportion of subjects who are free from device/procedure related Major Adverse Events (MAEs) that occur following the cryoablation procedure.</measure>
    <time_frame>12-months</time_frame>
    <description>MAEs include any of the following:
Death
Myocardial infarction
Cardiac perforation/pericardial tamponade
Cerebral infarct or systemic embolism
Major bleeding requiring transfusion of blood products
Mitral or tricuspid valve damage
Symptomatic pulmonary vein stenosis
Severe (≥ 70%) pulmonary vein stenosis
Permanent phrenic nerve injury
Access site complications requiring pharmacological or surgical intervention
Atrio-esophageal fistula
Pericarditis
Heart block requiring a permanent pacemaker
Vagal nerve injury with GI dysmotility
Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent Clinical Events Committee (CEC) as &quot;probably or definitely related&quot; to the Adagio System</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of the proportion of subjects receiving a single cryoablation who are free from any documented left atrial arrhythmia (AF/AFL/AT).</measure>
    <time_frame>12-months</time_frame>
    <description>The primary effectiveness endpoint will be based on a centralized core lab interpretation of the recordings used in the endpoint analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recording and analysis of all identified SAEs and SADEs through 12-months post-procedure.</measure>
    <time_frame>12-months</time_frame>
    <description>Events will be sub-stratified based on time to event as follows:
Early onset (procedure through 7-days post-ablation)
Peri-procedure (&gt; 7-days through 30-days post-ablation)
Late onset (&gt;30-days post ablation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the proportion of subjects with acute procedural (ablation) success</measure>
    <time_frame>20-minutes following last ablation</time_frame>
    <description>Documentation of pulmonary vein isolation and posterior wall isolation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>iCLAS Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ablation of the left and right atrium with the Adagio Medical iCLAS System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adagio AF Cryoablation System (iCLAS™)</intervention_name>
    <description>Endovascular ablation of the left and right atrium</description>
    <arm_group_label>iCLAS Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female between the ages of 18 - 80 years

        Currently scheduled for an ablation of symptomatic PsAF defined as continuous AF that is
        sustained &gt; 7-days and ≤ 12-months.

        Refractory to at least one class I or III AAD.

        Willingness, ability and commitment to participate in baseline and follow-up evaluations
        for the full length of the study

        Willingness and ability to give an informed consent

        Exclusion Criteria:

        Any duration of continuous AF lasting longer than 12-months

        History of previous left atrial ablation or surgical treatment for AF/AFL/AT

        Atrial fibrillation secondary to electrolyte imbalance, active thyroid disease, or any
        other reversible or non-cardiac cause

        Significant structural heart disease

        BMI &gt; 40

        ANY prior history of documented cerebral infarct or systemic embolism (excluding a
        post-operative DVT)

        Any prior history or current evidence of hemidiaphragmatic paralysis

        Pregnant or lactating (current or anticipated during study follow-up

        Vulnerable patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Holly Ng</last_name>
    <phone>949-348-1188</phone>
    <email>hng@adagiomedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nabil Jubran</last_name>
    <phone>949-348-1188</phone>
    <email>NJubran@adagiomedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grandview Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Burns, BSN, RN</last_name>
      <phone>205-971-7500</phone>
      <email>karen.burns@grandviewhealth.com</email>
    </contact>
    <investigator>
      <last_name>Jose Osorio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gustavo Morales, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anil Rajendra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory St. Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Barnes, RN, CCRC</last_name>
      <phone>678-843-6093</phone>
      <email>cynthia.barnes@emory.edu</email>
    </contact>
    <investigator>
      <last_name>David De Lurgio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Polites, BSN, RN, CCCRN-K</last_name>
      <phone>201-447-8453</phone>
      <email>spolite@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Suneet Mittal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dan Musat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

